The “Sustained Impact” of CGM – Dexcom’s Jake Leach from EASD

[podcast src=”https://html5-player.libsyn.com/embed/episode/id/28214234/height/90/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/3e9ccc/” width=”100%” scrolling=”no” class=”podcast-class” frameborder=”0″ placement=”top” primary_content_url=”http://traffic.libsyn.com/diabetesconnections/Ep_595_Final_Dexcom_EASD_Leach_V2.mp3″ libsyn_item_id=”28214234″ height=”90″ theme=”custom” custom_color=”3e9ccc” player_use_thumbnail=”use_thumbnail” use_download_link=”use_download_link” download_link_text=”Download the episode” /]Dexcom’s Chief Operating Officer Jake Leach talks to me about G6, G7, trends in CGM, what the company has its eye on next and answers a lot of your questions. This podcast is not intended as medical advice.…